FEMY - EXCLUSIVE: Femasys At Inflection Point And Undervalued Expects Growth Potential Following Roe v. Wade Overturn CEO Says | Benzinga
Femasys Inc (NASDAQ:FEMY) is a biomedical company focused on women’s healthcare.
The company, with a market capitalization of $22.50 million as of data from Benzinga Pro on 17 June, went public in June 2021.
In an emailed interview with Benzinga, Kathy Lee-Sepsick, the founder & CEO of Femasys, said, “I considered permanent birth control but found the available options too risky.”
Femasys’ commercially available products are:
- FemaSeed: A form of artificial insemination where sperm is delivered directly and safely into the fallopian tube
- FemVue: A contrast-generating device for ultrasound evaluation.
- FemCath: A delivery catheter for fallopian tube and uterine cavity evaluation
- FemCerv: An endocervical tissue sampler for diagnosis of cervical cancer.
The company is also developing FemBloc, a non-surgical permanent birth control, which is in late-stage clinical development.
Here’s a summary of the Q&A:
- Benzinga: How does Femasys place itself in the crowded ...